These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11591626)

  • 21. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopeptidase inhibitors.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
    Burrell LM; Farina NK; Balding LC; Johnston CI
    Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atrial natriuretic peptide mimetics and vasopeptidase inhibitors.
    Sagnella GA
    Cardiovasc Res; 2001 Aug; 51(3):416-28. PubMed ID: 11476732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New hormonal blockade strategies in cardiovascular disease.
    Johnston CI; Naitoh M; Risvanis J; Farina N; Burrell LM
    Scand Cardiovasc J Suppl; 1998; 47():61-6. PubMed ID: 9540135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
    Busse R; Hecker M
    Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
    Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
    J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of peptidases in the control of blood pressure.
    Kubota E; Dean RG; Balding LC; Burrell LM
    Essays Biochem; 2002; 38():129-39. PubMed ID: 12463166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinins and cardiovascular diseases.
    Su JB
    Curr Pharm Des; 2006; 12(26):3423-35. PubMed ID: 17017936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.